Increlex

Mecasermin, the active ingredient in Increlex, is a insulin-like growth factor-1 (IGF-1) analog presented as a sterile solution for subcutaneous use. It is indicated for children with primary IGF-1 deficiency or growth hormone gene deletion to support linear growth.

GNH USA supplies Increlex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Increlex is an IGF‑1 analog used to address growth disorders that stem from IGF‑1 deficiency. - Primary IGF‑1 deficiency: promotes linear growth in children lacking sufficient endogenous IGF‑1. - Growth hormone gene deletion: stimulates growth in children whose GH gene is non‑functional. - Severe growth failure associated with IGF‑1 deficiency: helps achieve height gain when conventional GH therapy is ineffective.

Adverse reactions may occur with Increlex administration.

Common Side Effects: - Injection site pain or erythema: local discomfort at the subcutaneous injection site. - Hypoglycemia: low blood glucose, especially when administered without adequate carbohydrate intake. - Headache: mild to moderate intensity. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Intracranial hypertension: signs include headache, visual changes, or papilledema. - Severe hypoglycemia: can lead to seizures or loss of consciousness. - Allergic reactions: rash, urticaria, or anaphylaxis. - Potential tumor progression: monitor patients with known malignancies.

Before initiating therapy, clinicians should consider several safety measures. - Blood glucose monitoring: check glucose levels before and after dosing to prevent hypoglycemia. - Dose adjustment: reduce dose if recurrent hypoglycemia occurs. - Intracranial pressure assessment: watch for symptoms of increased pressure, especially in patients with pre‑existing conditions. - Malignancy surveillance: evaluate risk in patients with a history of cancer. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Mecasermin may interact with other medicines that affect glucose metabolism or IGF‑1 activity.

Major Interactions (Avoid): - Insulin or insulin‑secretagogues (e.g., sulfonylureas): combined use can cause severe hypoglycemia. - Other IGF‑1 analogs: additive effects may increase risk of adverse events.

Moderate Interactions (Monitor Closely): - Glucocorticoids: may diminish the growth‑promoting effect of IGF‑1. - Thyroid hormone replacement: altered metabolism may require dose adjustments. - CYP450 inducers (e.g., rifampin): could reduce systemic exposure of Mecasermin.